| # | Drug | Count |
|---|---|---|
| 0 | NIRMATRELVIR AND RITONAVIR | 994 |
| 1 | DUPILUMAB | 499 |
| 2 | SECUKINUMAB | 384 |
| 3 | PREDNISONE | 328 |
| 4 | RAVULIZUMAB | 243 |
| 5 | ADALIMUMAB | 196 |
| 6 | OMALIZUMAB | 190 |
| 7 | METHOTREXATE SODIUM | 187 |
| 8 | METHOTREXATE | 176 |
| 9 | EFGARTIGIMOD ALFA | 174 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | EFGARTIGIMOD ALFA | 174 | 0.0439 |
| 1 | INFLIXIMAB-DYYB | 105 | 0.0305 |
| 2 | EFGARTIGIMOD ALFA AND HYALURONIDASE (HUMAN RECOMBINANT) | 13 | 0.0268 |
| 3 | AXATILIMAB-CSFR | 4 | 0.0245 |
| 4 | TEPROTUMUMAB | 123 | 0.0207 |
| 5 | NIRMATRELVIR AND RITONAVIR | 994 | 0.0184 |
| 6 | COAL TAR | 13 | 0.0165 |
| 7 | RILONACEPT | 13 | 0.0112 |
| 8 | USTEKINUMAB-STBA | 4 | 0.0108 |
| 9 | BRODALUMAB | 22 | 0.0107 |
| # | Drug class | Count |
|---|---|---|
| 0 | Corticosteroid [EPC] | 647 |
| 1 | Interleukin-4 Receptor alpha Antagonist [EPC] | 499 |
| 2 | Nonsteroidal Anti-inflammatory Drug [EPC] | 342 |
| 3 | Tumor Necrosis Factor Blocker [EPC] | 235 |
| 4 | Atypical Antipsychotic [EPC] | 198 |
| 5 | Anti-IgE [EPC] | 190 |
| 6 | Neonatal Fc Receptor Blocker [EPC] | 183 |
| 7 | CD20-directed Cytolytic Antibody [EPC] | 180 |
| 8 | Folate Analog Metabolic Inhibitor [EPC] | 173 |
| 9 | Estrogen [EPC] | 160 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Neonatal Fc Receptor Blocker [EPC] | 183 | 0.0417 |
| 1 | Interleukin-17 Receptor A Antagonist [EPC] | 22 | 0.0107 |
| 2 | Endoglycosidase [EPC] | 13 | 0.0070 |
| 3 | Classical Complement Pathway Inhibitor [EPC] | 2 | 0.0062 |
| 4 | Vitamin B6 Analog [EPC] | 2 | 0.0055 |
| 5 | Guanylate Cyclase-C Agonist [EPC] | 9 | 0.0043 |
| 6 | Interleukin-5 Receptor alpha-directed Cytolytic Antibody [EPC] | 82 | 0.0039 |
| 7 | Rifamycin Antibacterial [EPC] | 114 | 0.0031 |
| 8 | Neurokinin 3 Receptor Antagonist [EPC] | 7 | 0.0030 |
| 9 | Ectoparasiticide [EPC] | 10 | 0.0026 |